Cerebral rituximab uptake in multiple sclerosis: A 89Zr-immunoPET pilot study

Marloes Hj Hagens; Joep Killestein; Maqsood M Yaqub; Guus Ams van Dongen; Adriaan A Lammertsma; Frederik Barkhof; Bart Nm van Berckel

doi:https://doi.org/10.1177/1352458517704507

Cerebral rituximab uptake in multiple sclerosis: A 89Zr-immunoPET pilot study

Marloes Hj Hagens, Joep Killestein, Maqsood M Yaqub, Guus Ams van Dongen, Adriaan A Lammertsma, Frederik Barkhof, Bart Nm van Berckel

Research output: Contribution to journal › Article › Academic › peer-review

19 Citations (Scopus)

Abstract

Previous studies have demonstrated that the chimeric monoclonal antibody rituximab significantly reduces clinical and radiological disease activity in relapsing-remitting multiple sclerosis as early as 4 weeks after the first administration. The exact mechanisms leading to this rapid effect have not yet been clarified. The aim of this positron emission tomography study was to assess central nervous system penetration as a possible explanation, using zirconium-89-labelled rituximab. No evidence was found for cerebral penetration of [89Zr]rituximab.

Original language	English
Pages (from-to)	543-545
Journal	MULTIPLE SCLEROSIS
Volume	24
Issue number	4
Early online date	1 Apr 2017
DOIs	https://doi.org/10.1177/1352458517704507
Publication status	Published - Apr 2018

Keywords

B-lymphocytes
Multiple sclerosis
magnetic resonance imaging
monoclonal antibodies
positron emission tomography
rituximab

Access to Document

https://doi.org/10.1177/1352458517704507

Cite this

@article{27a1bcb3d6f2450db314e3b4b30772dd,

title = "Cerebral rituximab uptake in multiple sclerosis: A 89Zr-immunoPET pilot study",

abstract = "Previous studies have demonstrated that the chimeric monoclonal antibody rituximab significantly reduces clinical and radiological disease activity in relapsing-remitting multiple sclerosis as early as 4 weeks after the first administration. The exact mechanisms leading to this rapid effect have not yet been clarified. The aim of this positron emission tomography study was to assess central nervous system penetration as a possible explanation, using zirconium-89-labelled rituximab. No evidence was found for cerebral penetration of [89Zr]rituximab.",

keywords = "B-lymphocytes, Multiple sclerosis, magnetic resonance imaging, monoclonal antibodies, positron emission tomography, rituximab",

author = "Hagens, {Marloes Hj} and Joep Killestein and Yaqub, {Maqsood M} and {van Dongen}, {Guus Ams} and Lammertsma, {Adriaan A} and Frederik Barkhof and {van Berckel}, {Bart Nm}",

year = "2018",

month = apr,

doi = "https://doi.org/10.1177/1352458517704507",

language = "English",

volume = "24",

pages = "543--545",

journal = "MULTIPLE SCLEROSIS",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "4",

}

TY - JOUR

T1 - Cerebral rituximab uptake in multiple sclerosis

T2 - A 89Zr-immunoPET pilot study

AU - Hagens, Marloes Hj

AU - Killestein, Joep

AU - Yaqub, Maqsood M

AU - van Dongen, Guus Ams

AU - Lammertsma, Adriaan A

AU - Barkhof, Frederik

AU - van Berckel, Bart Nm

PY - 2018/4

Y1 - 2018/4

N2 - Previous studies have demonstrated that the chimeric monoclonal antibody rituximab significantly reduces clinical and radiological disease activity in relapsing-remitting multiple sclerosis as early as 4 weeks after the first administration. The exact mechanisms leading to this rapid effect have not yet been clarified. The aim of this positron emission tomography study was to assess central nervous system penetration as a possible explanation, using zirconium-89-labelled rituximab. No evidence was found for cerebral penetration of [89Zr]rituximab.

AB - Previous studies have demonstrated that the chimeric monoclonal antibody rituximab significantly reduces clinical and radiological disease activity in relapsing-remitting multiple sclerosis as early as 4 weeks after the first administration. The exact mechanisms leading to this rapid effect have not yet been clarified. The aim of this positron emission tomography study was to assess central nervous system penetration as a possible explanation, using zirconium-89-labelled rituximab. No evidence was found for cerebral penetration of [89Zr]rituximab.

KW - B-lymphocytes

KW - Multiple sclerosis

KW - magnetic resonance imaging

KW - monoclonal antibodies

KW - positron emission tomography

KW - rituximab

U2 - https://doi.org/10.1177/1352458517704507

DO - https://doi.org/10.1177/1352458517704507

M3 - Article

C2 - 28443358

SN - 1352-4585

VL - 24

SP - 543

EP - 545

JO - MULTIPLE SCLEROSIS

JF - MULTIPLE SCLEROSIS

IS - 4

ER -